Seasonal effect on fatigue, pain and dryness in primary Sjögren's syndrome.

Autoimmune diseases Clinical trials Epidemiology Outcome measures Patient-reported outcomes (PROs) Primary Sjögren’s syndrome Seasonality Seasons and rheumatic diseases

Journal

Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438

Informations de publication

Date de publication:
24 02 2020
Historique:
received: 06 07 2019
accepted: 06 02 2020
entrez: 26 2 2020
pubmed: 26 2 2020
medline: 25 11 2020
Statut: epublish

Résumé

To assess the presence of a seasonal effect on fatigue, pain and dryness in primary Sjögren's syndrome (pSS). Data (date; visual analogue scales (VAS) for pain, fatigue and dryness) were extracted from three randomised placebo-controlled trials (RCTs) evaluating infliximab (TRIPSS; n = 103 patients), hydroxychloroquine (JOQUER; n = 120 patients) and rituximab (TEARS; n = 120 patients) and from the 5-year follow-up of the ASSESS prospective cohort (n = 395 patients). Data were analysed at each visit for each patient, according to the day, the month of the year and the season. Linear mixed models were used to take into account the repeated structure of the data and to analyse a potential cyclic effect. A total of 744, 584, 848 and 682 pain, fatigue and dryness VASs were collected on 632 subjects in spring, summer, fall and winter, respectively. No significant difference was observed in pain, fatigue and dryness, according to the month of the year or the season (all p values > 0.05). In pSS, seasonality does not affect patient-reported outcomes (PROs) on fatigue, pain and dryness.

Sections du résumé

BACKGROUND
To assess the presence of a seasonal effect on fatigue, pain and dryness in primary Sjögren's syndrome (pSS).
METHODS
Data (date; visual analogue scales (VAS) for pain, fatigue and dryness) were extracted from three randomised placebo-controlled trials (RCTs) evaluating infliximab (TRIPSS; n = 103 patients), hydroxychloroquine (JOQUER; n = 120 patients) and rituximab (TEARS; n = 120 patients) and from the 5-year follow-up of the ASSESS prospective cohort (n = 395 patients). Data were analysed at each visit for each patient, according to the day, the month of the year and the season. Linear mixed models were used to take into account the repeated structure of the data and to analyse a potential cyclic effect.
RESULTS
A total of 744, 584, 848 and 682 pain, fatigue and dryness VASs were collected on 632 subjects in spring, summer, fall and winter, respectively. No significant difference was observed in pain, fatigue and dryness, according to the month of the year or the season (all p values > 0.05).
CONCLUSION
In pSS, seasonality does not affect patient-reported outcomes (PROs) on fatigue, pain and dryness.

Identifiants

pubmed: 32093783
doi: 10.1186/s13075-020-2118-1
pii: 10.1186/s13075-020-2118-1
pmc: PMC7041128
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

39

Références

PLoS One. 2013 May 24;8(5):e59868
pubmed: 23717383
Arthritis Care Res (Hoboken). 2011 Oct;63(10):1440-7
pubmed: 22121512
Clin Exp Rheumatol. 2006 Nov-Dec;24(6):702-4
pubmed: 17207389
Arthritis Rheum. 1991 Nov;34(11):1391-6
pubmed: 1953817
N Engl J Med. 2018 Jul 05;379(1):97
pubmed: 29972746
Ann Rheum Dis. 2009 Nov;68(11):1728-33
pubmed: 19029167
Pain. 2014 Apr;155(4):808-13
pubmed: 24462921
JAMA. 2014 Jul 16;312(3):249-58
pubmed: 25027140
J Rheumatol. 2017 Apr;44(4):473-481
pubmed: 28202741
Arthritis Rheum. 2009 Sep 15;61(9):1243-7
pubmed: 19714599
Ann Rheum Dis. 2011 Jun;70(6):968-72
pubmed: 21345815
Scand J Rheumatol. 1999;28(3):180-3
pubmed: 10380841
Lupus. 2008 Jan;17(1):6-10
pubmed: 18089676
Arthritis Rheum. 2004 Apr;50(4):1270-6
pubmed: 15077311
Ann Rheum Dis. 2002 Jun;61(6):554-8
pubmed: 12006334
Ann Rheum Dis. 2006 Aug;65(8):1093-8
pubmed: 16414971
Rheumatology (Oxford). 2007 May;46(5):846-8
pubmed: 17264092
J Rheumatol. 2012 Jul;39(7):1392-8
pubmed: 22660806
Ann Intern Med. 2014 Feb 18;160(4):233-42
pubmed: 24727841

Auteurs

Pierre-Marie Duret (PM)

Department of Rheumatology, Colmar General Hospital, Colmar, France. pierre-marie.duret@ch-colmar.fr.

Nicolas Meyer (N)

Department of Public Health, GMRC, Strasbourg University Hospital, Strasbourg, France.

Alain Saraux (A)

Department of Rheumatology, Brest University Hospital, Brest, France.

Valérie Devauchelle-Pensec (V)

Department of Rheumatology, Brest University Hospital, Brest, France.

Raphaele Seror (R)

Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, INSERM, Paris, France.

Véronique Le-Guern (V)

Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP-HP, Université Paris Descartes, Paris, France.

Claire Larroche (C)

Department of internal Medicine, Avicenne Hospital, Bobigny, France.

Aleth Perdriger (A)

Department of Rheumatology, Rennes University Hospital, Rennes, France.

Jean Sibilia (J)

Department of Rheumatology, Referral Center for Rare Autoimmune and Systemic Diseases, Strasbourg University Hospital, Strasbourg, France.

Vianney Guardiolle (V)

Department of Public Health, GMRC, Strasbourg University Hospital, Strasbourg, France.

Xavier Mariette (X)

Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, INSERM, Paris, France.

Jacques-Eric Gottenberg (JE)

Department of Rheumatology, Referral Center for Rare Autoimmune and Systemic Diseases, Strasbourg University Hospital, Strasbourg, France.
CNRS, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH